Classification performance of the 2023 ACR/EULAR antiphospholipid syndrome criteria: a systematic review and meta-analysis
Clicks: 3
ID: 325552
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
0.6
/100
3 views
2 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #69 of 202 articles by views in Lara D. Veeken
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 202 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
OBJECTIVES: To systematically evaluate the classification performance of the 2023 American College of Rheumatology/European Alliance of Associations for Rheumatology (ACR/EULAR) classification criteria for antiphospholipid syndrome (APS). METHODS: We conducted a systematic review of literature from August 2023 through May 2026, including studies that evaluated the ability of the 2023 ACR/EULAR APS criteria to classify patients previously classified according to expert clinical diagnosis and/or the 2006 revised Sapporo (Sydney) criteria. Data on true and false positives and negatives were extracted. Sensitivity and specificity were pooled using a bivariate random-effects model when both parameters were available; sensitivity was additionally pooled using a univariate random-effects model. RESULTS: Twenty four studies comprising 25 data sets were included, of which 13 incorporated non-APS control groups. In the bivariate meta-analysis, pooled sensitivity was 0.74 (95%CI 0.67-0.81) and pooled specificity was 0.99 (95% CI 0.98-1.00). Sensitivity demonstrated substantial heterogeneity across studies and varied markedly by APS phenotype. Sensitivity was low in obstetric APS (pooled sensitivity 0.20 in studies restricted to obstetric APS and 0.31 when obstetric subgroup data from additional studies were included), whereas it was higher among cases of thrombotic APS (0.82). Across cohorts, non-classification was mainly driven by isolated IgM antiphospholipid antibody positivity and obstetric APS phenotypes. CONCLUSION: The 2023 ACR/EULAR APS classification criteria exhibit consistently excellent specificity but reduced and phenotype-dependent sensitivity. These findings reinforce the intended role of the criteria for classification rather than clinical diagnosis and highlight important limitations in specific APS subgroups.
| Reference Key |
openalex_W7203770408
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Leyre Riancho-Zarrabeitia, José A Riancho |
| Journal | Lara D. Veeken |
| Year | 2026 |
| DOI |
10.1093/rheumatology/keag434
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.